countries. The range of services has varied, encompassing GMP and quality control consulting, regulatory affairs, training, as well as project management for radiopharmaceutical facilities construction overseas. In February 2023, Beforpharma secured a patent for the radiolabeling process of 68Ga-PSMA radiopharmaceutical. Currently, Beforpharma is involved in small-scale preparation of radiopharmaceuticals (in particular, 68Ga-PSMA and 68Ga-DOTATOC) at the hospital radiopharmacy. Upon the completion of the Beforpharma manufacturing site, the company's objective is to expand its business by leveraging advanced technological solutions integrated into its facility for the large-scale manufacturing of radiopharmaceutical products.